DigestRedComo funciona
Red
/
Empresas
Am
No verificado

Amphista Therapeutics

Sobre qué escribimos

Anuncios brevesBiotecnologíaPublicidad/Marketing/Medios de comunicación/Comunicación

11 Comunicados de prensa

Ver todos los comunicados de prensa
25/11/2025
Biotecnología
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Amphista Therapeutics announces new AMX-883 data to be presented at the ASH Annual Meeting and Exposition and provides a business progress update
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
28/10/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
27/10/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
23/10/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
15/10/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
23/09/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
17/09/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Amphista Therapeutics discloses first details of its SMARCA2 degrader program
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
16/07/2025
Biotecnología
Anuncios breves
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
22/05/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Amphista Therapeutics showcases cryo-EM enabled platform for discovering novel Targeted Glue™ degraders at SLAS Europe 2025
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
Press Release cover image
20/03/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Amphista Therapeutics to present novel mechanism of action for the degradation of BRD9 using its proprietary Targeted Glue® technology at two key upcoming scientific conferences
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0